米国の核医学市場規模、シェア、動向分析レポート：製品別、用途別、最終用途別、国別、セグメント予測、2024年～2030年

米国の核医学市場の成長と動向：

Grand View Research社の最新レポートによると、米国の核医学市場規模は2024年から2030年にかけて12.6％のCAGRを記録し、2030年には122億7,000万米ドルに達すると予測されています。

この市場を牽引しているのは、主にがんと心血管疾患の罹患率の増加です。CDCの2023年5月の推計によると、米国では年間約80万5,000人が心臓発作を目撃しており、そのうち60万5,000人が心臓発作の初回エピソードを目撃しています。

そのため、米国政府は2018年から2019年にかけて、心臓病の予防と治療に毎年約2,390億米ドルを費やしています。これには医薬品や医療サービスの費用が含まれます。飲酒、不適切な食事、運動不足などの特定の要因は、がんや心臓関連疾患を引き起こす可能性があります。したがって、米国ではがんと心血管疾患の発生率が急速に増加しており、核医学の需要が高まる可能性が高いです。がんの有病率が全体的に上昇すれば、治療を受ける患者数が増加し、早期診断と治療の必要性が高まるため、市場の成長が促進されます。

核医学の技術的進歩は核医学市場の成長促進要因です。テクネチウム-99mは、放射性医薬品の領域で最も広く利用されている放射性同位元素の1つとして際立っています。テクネチウム-99m以外に広く利用されている放射性同位元素には、ヨウ素131、インジウム111、フッ素18などがあります。これらの医療用アイソトープは放射線薬理学において重要な役割を果たしており、実験室内での薬物の分布や移動の研究を容易にしています。さらに、FDAによる最近の承認は、核医学市場のさらなる拡大を促進すると予想されています。

2023年9月、米国FDAは、サイクロファーム社が開発したテクネガスを、肺塞栓症の診断のための核医学灌流/換気肺スキャンに使用することを承認しました。テクネガス技術を用いた換気シンチグラフィーでは、テクネチウム-99m（Tc-99m）標識カーボンナノ粒子（CNP）が使用されます。ガンマカメラによる肺のイメージングを受ける前に、患者は薬剤で生成されたナノ粒子を吸入し、サイクロファームの子会社であるサイクロメディカが製造するオンサイトジェネレーターを使ってエアロゾル化されます。

正確な診断・治療法に対する需要の高まりが、核医学市場の成長促進要因となっています。現在、化学療法や放射線療法など、利用可能ながん治療の選択肢は、薬剤や放射線の使用を伴うが、その精度は完全ではないかもしれないです。さらに、これらの治療法には、全身または標的部位周辺の健康な臓器に影響を及ぼすという大きな欠点があります。放射性同位元素は、周囲の臓器に影響を与えることなく、腫瘍を特異的に標的にすることができるため、これらの技術よりも優れています。したがって、これらの診断・治療法に関連する利点が、これらの分野における放射性医薬品の需要を押し上げる可能性が高いです。核医学に対するニーズの高まりに対応するためのイニシアチブをとる組織の増加が、市場の成長を後押しすると予想されます。例えば、2023年8月、米国国家核安全保障局（NNSA）は、今後20年間で核関連の研究・生産インフラを近代化するために数百億米ドルを費やす計画でした。これにより、核医学処置への患者のアクセスが拡大し、全体的な健康と福祉が向上すると推定されます。

がんや心血管疾患などの慢性疾患の有病率の増加と、これらの疾患の治療における既存の治療手法に対するより良い選択肢としての核医学の出現は、市場の成長にプラスの影響を与えると予想されます。2023年3月の米国生物工学情報センター（NCBI）によると、米国では毎年約2,000万件の核医学・画像診断が実施されています。需要の増加に対応するため、各社は新しい加速器技術、検出器システム、放射化学、画像処理ソフトウェア、さまざまな疾患の診断と治療のための自動処理モジュールの研究開発に投資しています。

米国の核医学市場レポートハイライト

• 製品別では、診断製品が2023年に71.2%の最大売上シェアを占めました。これは、大規模な患者基盤の存在と、単一光子放出コンピュータ断層撮影法（SPECT）や陽電子放出断層撮影法（PET）のような先進技術の利用可能性による。
• 用途別では、腫瘍分野が市場を独占しており、予測期間中もその優位性を維持すると予測されています。これは、がんの罹患率が高く、放射性医薬品による診断が好まれるようになったためです。Iomab-B（AML適応）のような放射線治療薬が承認される可能性が高く、対象患者数の増加も相まって、市場成長の原動力になると予想されます。
• 最終用途別では、病院分野が市場を独占し、最大の売上シェアを占めています。同セグメントは予測期間中も優位を維持するとみられます。米国の核医学市場は、病院や診療所の増加により拡大しています。疾患の診断と治療のための入院患者の増加により、核医学製品に対する需要は高いです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国の核医学市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場牽引要因分析
  • 市場抑制要因分析
• 米国の核医学市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
  • 価格分析
  • パイプライン分析
  • 施術件数分析

第4章 米国の核医学市場：製品の推定・動向分析

• 米国の核医学市場：製品ダッシュボード
• 米国の核医学市場：製品変動分析
• 米国の核医学市場（製品別、収益別）
• 診断製品
• 治療製品

第5章 米国の核医学市場：製品の推定・動向分析

• 米国の核医学市場：製品ダッシュボード
• 米国の核医学市場：製品変動分析
• 米国の核医学市場（製品別、処置量）
• 診断施術
• 神経学
• 腫瘍学
• 甲状腺
• 神経学
• 腫瘍学
• 甲状腺
• リンパ腫
• 骨転移
• 内分泌腫瘍
• 肺スキャン
• その他

第6章 米国の核医学市場：最終用途の推定・動向分析

• 米国の核医学市場：最終用途ダッシュボード
• 米国の核医学市場：最終用途変動分析
• 米国の核医学市場（最終用途別、収益別）
• 病院・クリニック
• 診断センター
• その他

第7章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • 主要ディストリビューターおよびチャネルパートナーのリスト
  • 主要顧客
  • 主要企業の市場シェア分析、2023年
  • Eckert &Ziegler
  • Curium
  • GE Healthcare
  • Jubilant Life Sciences Ltd.
  • Bracco Imaging SPA
  • Nordion（Canada）, Inc.
  • The Institute For Radioelements（IRE）
  • NTP Radioisotopes SOC Ltd.
  • EczacIbasI-Monrol
  • Lantheus Medical Imaging, Inc.
  • The Australian Nuclear Science and Technology Organization
  • Novartis（Advanced Accelerator Applications）
  • Siemens Healthineers AG

List of Tables

• Table 1 List of abbreviation
• Table 2 U.S. Nuclear Medicine Market, 2018 - 2030 (USD Million)
• Table 3 U.S. Nuclear Medicine Market, by Product, 2018 - 2030 (USD Million)
• Table 4 U.S. Nuclear Medicine Market, by Product (Procedural Volume), 2018 - 2030 (Number of procedures)
• Table 5 U.S. Nuclear Medicine Market, by Application, 2018 - 2030 (USD Million)
• Table 6 U.S. Nuclear Medicine Market, by End-use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in U.S.
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD Modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 U.S. Nuclear Medicine Market: market outlook
• Fig. 10 Parent market outlook
• Fig. 11 Related/ancillary market outlook
• Fig. 12 U.S. Nuclear Medicine Market driver impact
• Fig. 13 U.S. Nuclear Medicine Market restraint impact
• Fig. 14 U.S. Nuclear Medicine Market: Product movement analysis
• Fig. 15 U.S. Nuclear Medicine Market: Product outlook and key takeaways
• Fig. 16 Diagnostic Products market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 17 SPECT market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 18 TC-99m market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 19 TL-201 market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 20 GA-67 market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 21 I-123 market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Other SPECT Products market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 PET market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 24 F-18 market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 25 SR-82/RB-82 market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 26 Other PET products market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Therapeutic Products market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 Alpha Emitters market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 29 RA-223 market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 30 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 Beta Emitters products market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 I-131 market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 33 Y-90 market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 34 SM-153 market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 35 Re-186 market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 36 Lu-117 market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 37 Other Beta Emitters market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 38 Brachytherapy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 39 Cesium-131 market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 40 Iodine-125 market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 41 Palladium-103 market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 42 Iridium-192 market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 43 Other Brachytherapy Products market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 44 Diagnostic procedures estimate and forecast, 2018 - 2030 (Number of procedures)
• Fig. 45 SPECT procedures estimate and forecast, 2018 - 2030 (Number of procedures)
• Fig. 46 PET procedures estimate and forecast, 2018 - 2030 (Number of procedures)
• Fig. 47 Therapeutic procedures estimate and forecast, 2018 - 2030 (Number of procedures)
• Fig. 48 U.S. Nuclear Medicine Market: Application movement analysis
• Fig. 49 U.S. Nuclear Medicine Market: Application outlook and key takeaways
• Fig. 50 Cardiology market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 51 SPECT market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 52 PET market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 53 Therapeutic Applications market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 54 Neurology market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 55 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 56 Thyroid Market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 57 SPECT market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 58 Therapeutic Applications market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 59 Lymphoma market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 60 Bone Metastasis market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 61 SPECT market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 62 Therapeutic Applications market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 63 Endocrine Tumor market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 64 Pulmonary Scans market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 65 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 66 U.S. Nuclear Medicine Market: End-use movement analysis
• Fig. 67 U.S. Nuclear Medicine Market: End-use outlook and key takeaways
• Fig. 68 Hospitals & Clinics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 69 Diagnostic Centers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 70 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 71 U.S. Nuclear Medicine Market: Country movement analysis
• Fig. 72 U.S. Nuclear Medicine Market: Country outlook and key takeaways
• Fig. 73 U.S. Nuclear Medicine Market share and leading players
• Fig. 74 Market share of key market players- U.S. Nuclear Medicine Market

U.S. Nuclear Medicine Market Growth & Trends:

The U.S. nuclear medicine market size is anticipated to reach USD 12.27 billion by 2030, registering a CAGR of 12.6%, from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the increasing incidence of cancer and cardiovascular diseases. Cardiovascular diseases are the leading cause of death for people of most ethnic and racial groups in the U.S. According to the CDC estimates in May 2023, Division for Heart Disease and Stroke Prevention, in the U.S., about 805,000 people witness heart attack annually, of these 605,000 people witness first episode of heart attack.

Therefore, the U.S. government spent around USD 239 billion every year from 2018 to 2019 on prevention and treatment of heart diseases. This includes the cost of medicines and health care services. Certain factors such as alcohol consumption, improper diet, and lack of exercise can cause cancer and heart-related diseases. Hence, the rapid increase in the incidence of cancer and cardiovascular disorders is likely to boost the demand for nuclear medicine in the U.S. The overall increase in the prevalence of cancer will likely boost the number of patients undergoing treatment, which increases the need for early diagnosis and treatment, thereby driving market growth.

Technological advancement in the nuclear medicine is a growth driver for the nuclear medicine market. Technetium-99m stands out as one of the most extensively utilized radioisotopes in the realm of radiopharmaceuticals. Alongside Technetium-99m, other widely employed radioisotopes include Iodine-131, Indium-111, and Fluorine-18. These medical isotopes play crucial roles in radiopharmacology, facilitating the study of drug distribution and movement within laboratory subjects. Furthermore, recent approvals by the FDA are anticipated to catalyze further expansion in the nuclear medicine market.

In September 2023, the U.S. FDA approved Technegas developed by Cyclopharm for use in nuclear medicine perfusion/ventilation lung scans to diagnose pulmonary embolism. Technetium-99m (Tc-99m)-labeled Carbon Nanoparticles (CNP) are used in ventilation scintigraphy using the technology Technegas. Before undergoing lung imaging with a gamma camera, patients inhale the agent-produced nanoparticles, which are then aerosolized using on-site generators manufactured by Cyclopharm's subsidiary Cyclomedica.

Rising demand for accurate diagnostic & treatment methods serves as a growth driver for the nuclear medicine market. Currently, available cancer treatment options, such as chemotherapy and radiation therapy, involve the use of drugs & radiation, which may not be completely accurate. Moreover, these therapies have a major disadvantage of affecting the whole body or the healthy organs surrounding the target site. Radioisotopes offer an advantage over these techniques as they can specifically target the tumor without affecting the surrounding body parts. Thus, benefits associated with these diagnostic and treatment procedures will likely boost the demand for radiopharmaceuticals in these fields. An increase in organizations undertaking initiatives to help address the growing need for nuclear medicine is anticipated to impel market growth. For instance, in August 2023, National Nuclear Security Administration (NNSA) was planning to spend tens of billions of dollars to modernize its nuclear-related research and production infrastructure over the next two decades in the U.S. This is expected to expand patient access to nuclear medicine procedures, which is estimated to improve their overall health and wellbeing.

Increasing prevalence of chronic diseases, such as cancer and cardiovascular diseases, and emergence of nuclear medicine as a better option to existing treatment methodologies for treatment of these diseases is anticipated to have a positive impact on market growth. According to National Center for Biotechnology Information (NCBI) in March 2023, around 20 million nuclear medicine & imaging procedures are conducted every year in the U.S. This rising volume of these procedures is expected to open new avenues in the market during the forecast period. To meet the increasing demand, companies are investing in R&D of new accelerator technology, detector systems, radiochemistry, imaging software, and automated processing modules for diagnosis and treatment of various diseases.

U.S. Nuclear Medicine Market Report Highlights:

• Based on product, diagnostic products held the largest revenue share of 71.2% in 2023 owing to presence of large patient base and availability of advanced technologies such as Single-Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET)
• Based on application, the oncology segment dominated the market and is anticipated to maintain its dominance over the forecast period. This is attributed to the high prevalence of cancer and increased preference for radiopharmaceutical diagnosis. The probable approval of radiotherapeutic agents such as Iomab-B (indicated for AML), coupled with growing target patient population, is expected to drive market growth
• Based on end-use, the hospitals segment dominated the market and accounted for the largest revenue share. The segment is expected to continue its dominance over the forecast period. The nuclear medicine market in the U.S. is expanding due to the rise in the number of hospitals and clinics. The demand for nuclear medicine products is high owing to rising inpatient visits for diagnosis and treatment of diseases

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. End-use
  • 1.2.4. Country scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in U.S.
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product
  • 2.2.2. Application
  • 2.2.3. End-use
  • 2.2.4. Country outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Nuclear Medicine Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising incidence of cancer and cardiovascular diseases
    • 3.2.1.2. Technological advancement in nuclear medicine
    • 3.2.1.3. Growing demand for accurate diagnostic & treatment methods
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Stringent regulations pertaining to production, storage, and usage nuclear medicines
    • 3.2.2.2. High cost associated with diagnostic and therapeutic procedures
• 3.3. U.S. Nuclear Medicine Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pricing Analysis
  • 3.3.4. Pipeline Analysis
  • 3.3.5. Procedural Volume Analysis
    • 3.3.5.1. Diagnostic Procedures
    • 3.3.5.1.1. SPECT
    • 3.3.5.1.2. PET
    • 3.3.5.2. Therapeutic Procedure

Chapter 4. U.S. Nuclear Medicine Market: Product Estimates & Trend Analysis

• 4.1. U.S. Nuclear Medicine Market: Product Dashboard
• 4.2. U.S. Nuclear Medicine Market: Product Movement Analysis
• 4.3. U.S. Nuclear Medicine Market by Product, Revenue
• 4.4. Diagnostic Products
  • 4.4.1. Diagnostic Products market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. SPECT
    • 4.4.2.1. SPECT market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.1.1. TC-99m
    • 4.4.2.1.2. TL-201
    • 4.4.2.1.3. GA-67
    • 4.4.2.1.4. I-123
    • 4.4.2.1.5. Other SPECT Products
  • 4.4.3. PET
    • 4.4.3.1. PET market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3.1.1. F-18
    • 4.4.3.1.2. SR-82/RB-82
    • 4.4.3.1.3. Other PET products
• 4.5. Therapeutic Products
  • 4.5.1. Therapeutic Products market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.2. Alpha Emitters
    • 4.5.2.1. Alpha Emitters market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2.1.1. RA-223
    • 4.5.2.1.2. Others
  • 4.5.3. Beta Emitters
    • 4.5.3.1. Beta Emitters market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.3.1.1. I-131
    • 4.5.3.1.2. Y-90
    • 4.5.3.1.3. SM-153
    • 4.5.3.1.4. Re-186
    • 4.5.3.1.5. Lu-117
    • 4.5.3.1.6. Other Beta Emitters
  • 4.5.4. Brachytherapy
    • 4.5.4.1. Brachytherapy market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.4.1.1. Cesium-131
    • 4.5.4.1.2. Iodine-125
    • 4.5.4.1.3. Palladium-103
    • 4.5.4.1.4. Iridium-192
    • 4.5.4.1.5. Other Brachytherapy Products

Chapter 5. U.S. Nuclear Medicine Market: Product Estimates & Trend Analysis

• 5.1. U.S. Nuclear Medicine Market: Product Dashboard
• 5.2. U.S. Nuclear Medicine Market: Product Movement Analysis
• 5.3. U.S. Nuclear Medicine Market by Product (Procedural Volume)
• 5.4. Diagnostic Procedures
  • 5.4.1. Diagnostic Procedures market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. SPECT
    • 5.4.2.1. SPECT market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. PET
    • 5.4.3.1. PET market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.4. Therapeutic Applications
    • 5.4.4.1. Therapeutic applications market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Neurology
  • 5.5.1. Neurology market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Oncology
  • 5.6.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Thyroid
  • 5.7.1. Thyroid market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.2. SPECT
    • 5.7.2.1. SPECT market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.3. Therapeutic Applications
    • 5.7.3.1. Therapeutic applications market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. Neurology
  • 5.8.1. Neurology market estimates and forecasts 2018 to 2030 (USD Million)
• 5.9. Oncology
  • 5.9.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
• 5.10. Thyroid
  • 5.10.1. Thyroid market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.10.1.1. SPECT
    • 5.10.1.2. SPECT market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.10.1.3. Therapeutic Applications
    • 5.10.1.4. Therapeutic applications market estimates and forecasts 2018 to 2030 (USD Million)
• 5.11. Lymphoma
  • 5.11.1. Lymphoma market estimates and forecasts 2018 to 2030 (USD Million)
• 5.12. Bone Metastasis
  • 5.12.1. Bone Metastasis market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.12.1.1. SPECT
    • 5.12.1.2. SPECT market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.12.1.3. Therapeutic Applications
    • 5.12.1.4. Therapeutic applications market estimates and forecasts 2018 to 2030 (USD Million)
• 5.13. Endocrine Tumor
  • 5.13.1. Endocrine Tumor market estimates and forecasts 2018 to 2030 (USD Million)
• 5.14. Pulmonary Scans
  • 5.14.1. Pulmonary Scans market estimates and forecasts 2018 to 2030 (USD Million)
• 5.15. Others
  • 5.15.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Nuclear Medicine Market: End-use Estimates & Trend Analysis

• 6.1. U.S. Nuclear Medicine Market: End-use Dashboard
• 6.2. U.S. Nuclear Medicine Market: End-use Movement Analysis
• 6.3. U.S. Nuclear Medicine Market by End-use, Revenue
• 6.4. Hospitals & Clinics
  • 6.4.1. Hospitals & Clinics market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Diagnostic Centers
  • 6.5.1. Diagnostic Centers market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.1.1.

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company market share analysis, 2023
  • 7.3.4. Eckert & Ziegler
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Curium
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Product benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. GE Healthcare
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Jubilant Life Sciences Ltd.
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. Bracco Imaging S.P.A
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. Nordion (Canada), Inc.
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. The Institute For Radioelements (IRE)
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Product benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. NTP Radioisotopes SOC Ltd.
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Product benchmarking
    • 7.3.11.4. Strategic initiatives
  • 7.3.12. EczacIbasI-Monrol
    • 7.3.12.1. Company overview
    • 7.3.12.2. Financial performance
    • 7.3.12.3. Product benchmarking
    • 7.3.12.4. Strategic initiatives
  • 7.3.13. Lantheus Medical Imaging, Inc.
    • 7.3.13.1. Company overview
    • 7.3.13.2. Financial performance
    • 7.3.13.3. Product benchmarking
    • 7.3.13.4. Strategic initiatives
  • 7.3.14. The Australian Nuclear Science and Technology Organization
    • 7.3.14.1. Company overview
    • 7.3.14.2. Financial performance
    • 7.3.14.3. Product benchmarking
    • 7.3.14.4. Strategic initiatives
  • 7.3.15. Novartis (Advanced Accelerator Applications)
    • 7.3.15.1. Company overview
    • 7.3.15.2. Financial performance
    • 7.3.15.3. Product benchmarking
    • 7.3.15.4. Strategic initiatives
  • 7.3.16. Siemens Healthineers AG
    • 7.3.16.1. Company overview
    • 7.3.16.2. Financial performance
    • 7.3.16.3. Product benchmarking
    • 7.3.16.4. Strategic initiatives